Diclofenac-Teva gel naruzhn.prim-I 1% 100g


Diclofenac-Teva gel naruzhn.prim-I 1% 100g



Active substance:
100 g of the preparation contains: Sodium diclofenac 1.000 g ;.
5,000 g of diisopropyl adipate; giproloza 2.000 g; 90% lactic acid 0.044 g; Sodium disulphite 0.050 g; 40,000 g of isopropanol; Purified water 51.906 g
The clear, colorless gel with characteristic odor.
Product form:
Gel for external application of 1%.
40 g or 100 g in an aluminum tube, covered with aluminum foil for controlling the first opening with a screw cap. 1 the tube together with instructions for use placed in a cardboard box.
Hypersensitivity to diclofenac or to other components of the formulation; tendency to the emergence of attacks of bronchial asthma, skin rashes or acute rhinitis application of acetylsalicylic acid or other nonsteroidal antiinflammatory drugs; pregnancy (III trimester), breast-feeding; children’s age (12 years); violating the integrity of the skin at the intended site of application.
Hepatic porphyria (exacerbation), erosive and ulcerative lesions of the gastrointestinal tract, severe liver and kidney function, blood clotting disorders (including hemophilia, prolonged bleeding, bleeding tendency), chronic heart failure, asthma, older age, pregnancy (I and II trimester).
Back pain of inflammatory and degenerative diseases of the spine (sciatica, osteoarthritis, lumbago, sciatica); pain in the joints (. joints of the fingers, knee, etc.), rheumatoid arthritis, osteoarthritis; muscle pain (due to stretching, overvoltage, bruises, injuries); inflammation and swelling of the soft tissues and joints due to injuries and rheumatic diseases (tendonitis, bursitis, defeat periarticular tissues, CTS).
Interaction with other drugs
The drug can increase the effects of drugs that cause photosensitization. Clinically significant interactions are not described with other drugs.
Due to the low systemic absorption when applied to the gel, overdose unlikely.
In case of accidental ingestion may develop systemic side effects. Treatment of overdose Accidental ingestion: gastric lavage, induction of vomiting, activated charcoal, symptomatic therapy. Dialysis and diuresis are not effective in view of the high degree of diclofenac binding to plasma proteins (about 99%).
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID).
Gel for external use, the active ingredient is an antiinflammatory drug diclofenac -nesteroidny having pronounced analgesic, antiinflammatory and antipyretic properties.
Non-selectively inhibiting cyclooxygenase type 1 and 2, gives the arachidonic acid metabolism and the formation of proinflammatory prostaglandins in inflammation. Diclofenac is used to eliminate pain and inflammation in the joints, muscles and ligaments of traumatic or rheumatic origin, helping to reduce pain and swelling associated with inflammation, increasing joint mobility.
The amount of diclofenac absorbed through the skin, proportional to the treated surface area and depends on the total dose of drug applied and the degree of skin hydration. We measured the concentrations of diclofenac in plasma, synovial membrane and synovial fluid of the drug when applied to the affected joint area.
Maximum concentrations were approximately 100 times lower in plasma than after oral administration of the same amount of diclofenac. 99.7% diclofenac associated plasma proteins, mainly albumin (99.4%). Diclofenac advantageously distributed and retained in deep tissues prone to inflammation, such as joints, where its concentration is 20 times higher than in blood plasma.
Metabolism of diclofenac is achieved partly by glucuronidation unmodified molecule, but preferably by means of single and multiple hydroxylation which leads to the formation of several phenolic metabolites, most of which is converted to glucuronide conjugates. Two phenolic metabolites are biologically active, but to a much lesser extent than diclofenac.
Total systemic plasma clearance of diclofenac is 263 ± 56 mL / min. Terminal half-life is 1-2 hours. The half-life of the metabolites, including the two active pharmacologically, and also of short duration is 1-3 hours. One of the metabolites (3`-hydroxy-4′-metoksidiklofenak) has a longer half-life, however, this completely inactive metabolite. Most of diclofenac and its metabolites are excreted in the urine.
Pregnancy and breast-feeding
In the absence of data on the use of diclofenac in pregnant women, the use of the drug during the I and II trimester of pregnancy is recommended only on prescription by comparing the benefits to the mother and the risk to the fetus. Diclofenac is contraindicated in the III trimester of pregnancy due to the possibility of lowering the tone of the uterus and / or premature closure of the fetal blood flow.
In the absence of data on the penetration of diclofenac in breast milk drug is not recommended for use during breastfeeding. If you need to use the drug, it should not be applied to the breasts or to a large surface of the skin and do not use for a long time.
Conditions of supply of pharmacies
Without recipe.
side effects
The frequency of side effects is classified in accordance with the recommendations of the World Health Organization: very common (> 1/10); common (> 1/100, 1/1000 but but 1/10000, but
Infectious and parasitic diseases: very rare – pustular rash.
Immune system: very rarely – a generalized skin rash, allergic reactions (urticaria, hypersensitivity: angioedema).
The respiratory system and organs of thoracic and mediastinal disorders: very rare – asthma attacks, bronchospastic reactions.
For the skin: often – erythema, dermatitis, including contact dermatitis (symptoms of eczema, itching, swelling the treated area of ​​the skin, rash, papules, vesicles, desquamation); rare – bullous dermatitis; very rarely – photosensitivity reactions.
special instructions
Diclofenac-Teva should only be applied to intact skin, avoiding contact with open wounds. Do not allow contact with the drug in the mouth, eyes and mucous membranes. After applying the product allowed the imposition of bandage, but it should not impose an airtight occlusive dressings. In the case of skin rash after application of the preparation of its use should be discontinued.
Effects on ability to drive vehicles and mechanisms:
The drug has no effect on the ability to perform potentially hazardous activities that require high concentration and psychomotor speed reactions (road management, work with moving machinery).
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children!.
Dosing and Administration
Applied topically.
Adults and children over 12 years of drug applied to the skin 2 times a day (every 12 hours: preferably in the morning and evening), gently rubbing into the skin.
The required amount of the drug depends on the size of the painful area. A single dose of the preparation – 2 – 4 g (which is comparable in volume correspondingly to the size of a walnut or cherry) is sufficient for treatment zone area of ​​400-800 cm2. If the hands are not the area of ​​localization of pain after application of the drug need to be cleaned.
The duration of treatment depends on the indication and celebrated effect. The gel should not be used longer than 14 days post-traumatic inflammation and rheumatic diseases of soft tissues without doctor’s advice. If after 7 days of application of the therapeutic effect is not observed or the condition worsens, contact your doctor.
To remove the protective membrane screw cap should be used as a key (recess with projections on the outside of the cover). Align the groove on the outside of the lid with shaped protective membrane of the tube and turn. The membrane should be separated from the tube.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review